Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2020.107157 http://scihub22266oqcxt.onion/10.1016/j.intimp.2020.107157 33187911!7608018!33187911     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33187911&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Int+Immunopharmacol 2021 ; 90 (?): 107157 Nephropedia Template TP {{tp|p=33187911|t=2021. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 |pdf=|usr=}}{{33187911}} gab.com Text Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33187911 #FOAvip Coronavirus disease 2019 (COVID-19) pandemic has brought challenges to health and social care systems. However, the empirical use of antibiotics is still confusing. Presently, a total of 1123 patients with COVID-19 admitted to Renmin Hospital of Wuhan University was included in this retrospective cohort study. The clinical features, complications and outcomes were compared between the suspected bacterial infection and the no evidence of bacterial infection. The risk factors of mortality and the incidence of acute organ injury were analyzed. As a result, 473 patients were selected to suspected bacterial infection (SI) group based on higher white blood cell count and procalcitonin or bacterial pneumonia on chest radiography. 650 patients were selected to the no evidence of bacterial infection (NI) group. The SI group had more severely ill patients (70.2% vs. 39.8%), more death (20.5% vs. 2.2%), and more acute organ injury (40.2% vs. 11.2%). Antibiotics were found associated with improved mortality and an increased risk for acute organ injury in hospitalized patients with COVID-19. Intravenous moxifloxacin and meropenem increased the death rate in patients with suspected bacterial infection, while oral antibiotics reduced mortality in this group. Moreover, penicillin and meropenem treatments were associated with increased mortality of the patients with no evidence of bacterial infection. In conclusion, patients with suspected bacterial infection were more likely to have negative clinical outcomes than those without bacterial infection. Empirical use of antibiotics may not have the expected benefits. Twit Text FOAVip Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33187911 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33187911 #FOAvip English Wikipedia <ref>{{Cite pmid|33187911}}</ref> Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19 #MMPMID33187911 Liu C; Wen Y; Wan W; Lei J; Jiang X Int Immunopharmacol 2021[Jan]; 90 (?): 107157 PMID33187911show ga Coronavirus disease 2019 (COVID-19) pandemic has brought challenges to health and social care systems. However, the empirical use of antibiotics is still confusing. Presently, a total of 1123 patients with COVID-19 admitted to Renmin Hospital of Wuhan University was included in this retrospective cohort study. The clinical features, complications and outcomes were compared between the suspected bacterial infection and the no evidence of bacterial infection. The risk factors of mortality and the incidence of acute organ injury were analyzed. As a result, 473 patients were selected to suspected bacterial infection (SI) group based on higher white blood cell count and procalcitonin or bacterial pneumonia on chest radiography. 650 patients were selected to the no evidence of bacterial infection (NI) group. The SI group had more severely ill patients (70.2% vs. 39.8%), more death (20.5% vs. 2.2%), and more acute organ injury (40.2% vs. 11.2%). Antibiotics were found associated with improved mortality and an increased risk for acute organ injury in hospitalized patients with COVID-19. Intravenous moxifloxacin and meropenem increased the death rate in patients with suspected bacterial infection, while oral antibiotics reduced mortality in this group. Moreover, penicillin and meropenem treatments were associated with increased mortality of the patients with no evidence of bacterial infection. In conclusion, patients with suspected bacterial infection were more likely to have negative clinical outcomes than those without bacterial infection. Empirical use of antibiotics may not have the expected benefits. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Anti-Bacterial Agents/*therapeutic use[MESH] |Bacterial Infections/complications/*drug therapy/mortality[MESH] |COVID-19/complications/mortality[MESH] |China[MESH] |Cohort Studies[MESH] |Female[MESH] |Humans[MESH] |Leukocytes/*pathology[MESH] |Lung/*diagnostic imaging/pathology[MESH] |Male[MESH] |Middle Aged[MESH] |Pneumonia, Bacterial[MESH] |Procalcitonin/metabolism[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH] |SARS-CoV-2/*physiology[MESH]Clinical characteristics and antibiotics treatment in suspected bacter(epmc).pdf DeepDyve Pubget Overpricing